Axsome Therapeutics (AXSM) Net Income towards Common Stockholders (2015 - 2026)

Axsome Therapeutics has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$64.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 8.63% year-over-year to -$64.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$188.4 million (up 32.31% YoY) and the FY2025 annual result came in at -$183.2 million, up 36.21% from the prior year.
• Net Income towards Common Stockholders declined to -$64.5 million in Q1 2026 per AXSM's latest filing, from -$28.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$11.2 million in Q1 2023 and troughed at -$98.6 million in Q4 2023.
• A 5-year average of -$56.6 million and a median of -$61.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders jumped 81.04% in 2022, then slumped 508.27% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$61.2 million in 2022, then slumped by 61.06% to -$98.6 million in 2023, then grew by 24.05% to -$74.9 million in 2024, then soared by 61.78% to -$28.6 million in 2025, then slumped by 125.43% to -$64.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$64.5 million, -$28.6 million, and -$47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.